Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR4 | P22455 | 13/20 | 0.75 |
| ▸ | FGFR1 | P11362 | 12/20 | 0.75 |
| ▸ | FGFR2 | P21802 | 5/20 | 0.67 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.67 |
| ▸ | KDR | P35968 | 1/20 | 0.67 |
| ▸ | EGFR | P00533 | 3/20 | 0.64 |
| ▸ | SRC | P12931 | 1/20 | 0.58 |
| ▸ | ITK | Q08881 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14706440 | 0.91 | FGFR4 (0.74) | FGFR4FGFR1FGFR2FGFR3KDR | |
| SCHEMBL14706448 | 0.88 | FGFR4 (0.69) | FGFR4FGFR1FGFR2FGFR3KDR | |
| SCHEMBL19731399 | 0.87 | FGFR4 (0.80) | FGFR4FGFR1FGFR2FGFR3KDR | |
| SCHEMBL14706441 | 0.86 | FGFR4 (0.73) | FGFR4FGFR1FGFR2FGFR3KDR | |
| SCHEMBL14706442 | 0.86 | FGFR4 (0.63) | FGFR4FGFR1FGFR2FGFR3KDR | |
| SCHEMBL19731265 | 0.86 | FGFR4 (1.00) | FGFR4FGFR1FGFR2FGFR3KDR | |
| SCHEMBL17902988 | 0.86 | FGFR4 (1.00) | FGFR4FGFR1FGFR2FGFR3KDR | |
| SCHEMBL14706437 | 0.84 | ITK (0.80) | FGFR4FGFR1FGFR2FGFR3EGFR | |
| SCHEMBL14706449 | 0.83 | FGFR4 (0.71) | FGFR4FGFR1FGFR2FGFR3KDR | |
| SCHEMBL14706443 | 0.83 | FGFR4 (0.71) | FGFR4FGFR1FGFR2FGFR3KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9546172-B2 | Pyrazolo[3,4-d]pyrimidine and pyrazolo[2,3-d]pyrimidine compounds as kinase inhibitors | PHARMACYCLICS LLC (US) | 2017-01-17 | — | — | US | disclosed |
| US-9546172-B2 | Pyrazolo[3,4-d]pyrimidine and pyrazolo[2,3-d]pyrimidine compounds as kinase inhibitors | PHARMACYCLICS LLC (US) | 2017-01-17 | — | — | US | disclosed |
| US-9273051-B2 | Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors | PHARMACYCLICS LLC (US) | 2016-03-01 | — | — | US | disclosed |
| US-9273051-B2 | Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors | PHARMACYCLICS LLC (US) | 2016-03-01 | — | — | US | disclosed |
| US-20130172314-A1 | PYRAZOLO[3,4-d]PYRIMIDINE AND PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS AS KINASE INHIBITORS | PHARMACYCLICS, INC. (US) | 2013-07-04 | — | — | US | disclosed |
| US-20130172314-A1 | PYRAZOLO[3,4-d]PYRIMIDINE AND PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS AS KINASE INHIBITORS | PHARMACYCLICS, INC. (US) | 2013-07-04 | — | — | US | disclosed |
| WO-2013102059-A1 | PYRAZOLO [3, 4-D] PYRIMIDINE AND PYRROLO [2, 3-D] PYRIMIDINE COMPOUNDS AS KINASE INHIBITORS | PHARMACYCLICS, INC. (US) | 2013-07-04 | — | — | WO | disclosed |
| US-8377946-B1 | Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors | PHARMACYCLICS, INC. (US) | 2013-02-19 | — | — | US | disclosed |
| US-8377946-B1 | Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors | PHARMACYCLICS, INC. (US) | 2013-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130172314-A1 | PYRAZOLO[3,4-d]PYRIMIDINE AND PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS AS KINASE INHIBITORS | BTK, LCK, LYN | FGFR4 1542/4885FGFR1 1752/4885FGFR2 983/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.